Literature DB >> 7438656

Pharmacokinetics of prazosin in normotensive subjects after low oral doses.

M K Dynon, B Jarrott, O Drummer, W J Louis.   

Abstract

A method for measuring plasma prazosin concentrations is reported. This method, which involves high pressure liquid chromatography (HPLC) combined with fluorescence detection, has a sensitivity 20 times that of previous conventional fluorimetric techniques and twice that of other HPLC methods, and can be used to study the pharmacokinetics of prazosin at very low doses. Plasma prazosin concentrations were measured in 5 normal volunteers for 24 hours after single oral doses of 0.5 and 1.5mg of prazosin. On average, the lag time was 0.650 and 0.448 hours, and the elimination half-life 2.3 and 2.5 hours, for the 0.5 and 1.5mg doses, respectively. Peak prazosin concentrations occurred between 1.1 and 3.6 hours after dosing, and after the 1.5mg doses were associated with symptoms of faintness.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7438656     DOI: 10.2165/00003088-198005060-00007

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  4 in total

1.  The influence of food on the oral bioavailability of terazosin.

Authors:  J J McNeil; O H Drummer; K Raymond; E L Conway; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

2.  Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin.

Authors:  M G Scott; A H Deering; M T McMahon; D W Harron; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  The effect of a single oral dose of prazosin on venous reflex response, blood pressure and pulse rate in normal volunteers.

Authors:  G J Schapel; W H Betts
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of prazosin--1985.

Authors:  J Vincent; P A Meredith; J L Reid; H L Elliott; P C Rubin
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.